Skip to main content
PMC home page
Arthritis Research & Therapy logoLink to Arthritis Research & Therapy
. 2016 Oct 12;18:236. doi: 10.1186/s13075-016-1150-7

Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

Jeffrey N Miner 1,✉, Philip K Tan 1, David Hyndman 1, Sha Liu 1, Cory Iverson 1, Payal Nanavati 1, David T Hagerty 1, Kimberly Manhard 1, Zancong Shen 1, Jean-Luc Girardet 1, Li-Tain Yeh 1, Robert Terkeltaub 2, Barry Quart 1
PMCID: PMC5059967  PMID: 27733209

Erratum

Unfortunately, after publication of this article [1], it was noticed that the name of Jeffrey N. Miner was captured incorrectly during the production process. The middle initial ‘N’ was missing from the list. The corrected author list can be seen above and the original article has been updated to correct this error.

Footnotes

The online version of the original article can be found under doi:10.1186/s13075-016-1107-x.

Reference

  • 1.Miner JN, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, Hagerty DT, Manhard K, Shen Z, Girardet J-L, Yeh L-T, Terkeltaub R, Quart B. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther. 2016;18:214. doi: 10.1186/s13075-016-1107-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Arthritis Research & Therapy are provided here courtesy of BMC

RESOURCES